Pages that link to "Q54535188"
Jump to navigation
Jump to search
The following pages link to The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. (Q54535188):
Displaying 50 items.
- The Inositide Signaling Pathway As a Target for Treating Gastric Cancer and Colorectal Cancer (Q26744721) (← links)
- KRAS oncogene in lung cancer: focus on molecularly driven clinical trials (Q26765353) (← links)
- PI3K/Akt/mTOR inhibitors in breast cancer (Q26771394) (← links)
- Treatment Individualization in Colorectal Cancer (Q26776215) (← links)
- Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers (Q26781362) (← links)
- Molecular phenotypes of colorectal cancer and potential clinical applications (Q26785725) (← links)
- Splicing Regulators and Their Roles in Cancer Biology and Therapy (Q26798158) (← links)
- What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway (Q26825780) (← links)
- Pathways and therapeutic targets in melanoma (Q26865736) (← links)
- Targeted therapies in development for non-small cell lung cancer (Q27022852) (← links)
- Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma (Q27852994) (← links)
- Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade (Q27853295) (← links)
- Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression (Q27853310) (← links)
- Maximising the potential of AKT inhibitors as anti-cancer treatments (Q28072254) (← links)
- Combination treatment including targeted therapy for advanced hepatocellular carcinoma (Q28077738) (← links)
- Targeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes? (Q28079596) (← links)
- RSK3: A regulator of pathological cardiac remodeling (Q28086916) (← links)
- Cytoprotection "gone astray": Nrf2 and its role in cancer (Q28393784) (← links)
- Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs (Q28547522) (← links)
- Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK (Q28833740) (← links)
- PI3K and cancer: lessons, challenges and opportunities (Q30080017) (← links)
- Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth. (Q30252408) (← links)
- Understanding, recognizing, and managing toxicities of targeted anticancer therapies (Q33408049) (← links)
- Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors (Q33439312) (← links)
- Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors (Q33571352) (← links)
- The selective MEK1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivo (Q33591361) (← links)
- Therapeutic sensitivity to Rac GTPase inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancer (Q33591690) (← links)
- Zeylenone, a naturally occurring cyclohexene oxide, inhibits proliferation and induces apoptosis in cervical carcinoma cells via PI3K/AKT/mTOR and MAPK/ERK pathways (Q33687272) (← links)
- Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development (Q33776641) (← links)
- Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models (Q33820374) (← links)
- Bilateral blockade of MEK- and PI3K-mediated pathways downstream of mutant KRAS as a treatment approach for peritoneal mucinous malignancies. (Q33825288) (← links)
- Deciphering combinations of PI3K/AKT/mTOR pathway drugs augmenting anti-angiogenic efficacy in vivo (Q34075366) (← links)
- The MAPK pathway as an apoptosis enhancer in melanoma (Q34104135) (← links)
- Oncogenic KRAS signalling in pancreatic cancer (Q34113460) (← links)
- Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations (Q34153696) (← links)
- MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer (Q34203585) (← links)
- Inhibition of fatty acid synthase induces pro-survival Akt and ERK signaling in K-Ras-driven cancer cells (Q34223118) (← links)
- Development of siRNA payloads to target KRAS-mutant cancer (Q34287993) (← links)
- Novel somatic mutations to PI3K pathway genes in metastatic melanoma (Q34389570) (← links)
- Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors (Q34525925) (← links)
- miR-126&126* restored expressions play a tumor suppressor role by directly regulating ADAM9 and MMP7 in melanoma. (Q34599550) (← links)
- mTOR inhibition elicits a dramatic response in PI3K-dependent colon cancers (Q34673900) (← links)
- A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors (Q34818301) (← links)
- Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models (Q35018805) (← links)
- Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas (Q35033377) (← links)
- Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors (Q35051964) (← links)
- Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: analysis of 1806 cases. (Q35068021) (← links)
- mTOR inhibition induces compensatory, therapeutically targetable MEK activation in renal cell carcinoma (Q35236736) (← links)
- Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials. (Q35462692) (← links)
- Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer (Q35657842) (← links)